Take a fresh look at your lifestyle.

Dow Jones Newswires: FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics

A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics BCLI, -8.35% for amyotrophic lateral sclerosis, or ALS.

The FDA panel’s vote was 17-1, with one adviser abstaining.

Patients last year petitioned the FDA to consider the treatment, called NurOwn, in a public hearing. The agency said the company submitted “scientifically incomplete” and “grossly deficient” data.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More